Bli medlem
Bli medlem

Du är här


Novavax, Inc.: Novavax Announces Closing of Public Offering

GAITHERSBURG, Md., March 31, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced the closing of the underwritten public offering
priced on Wednesday, March 25, 2015.

The company issued 27,758,620 shares of its common stock, including 3,620,689
shares pursuant to the underwriters' option to purchase additional shares.
The shares were issued at $7.25 per share resulting in total gross proceeds
from this offering of approximately $201,250,000 before deducting the
underwriters discount and offering expenses.

Novavax intends to use a portion of the net proceeds from this offering for
the advancement of its lead vaccine candidates, including the preparation and
potential initiation of Phase 3 clinical trials of its elderly RSV and
maternal RSV programs, as well as its other clinical and preclinical research
programs and general corporate purposes, including working capital, product
development, manufacturing and process development expenditures and capital
expenditures, as well as acquisitions and other strategic purposes.

J.P. Morgan and Citigroup acted as joint book-running managers of the
offering. Piper Jaffray&Co. and Wedbush PacGrow acted as Co-Lead Managers,
Janney Montgomery Scott and Ladenburg Thalmann acted as Co-Managers.

The shares described above were issued pursuant to a final prospectus
supplement and accompanying prospectus. The company filed the final
prospectus supplement relating to the offering with the Securities and
Exchange Commission ("SEC") on March 26, 2015, which is available along with
the accompanying prospectus filed with the SEC in connection with the
company's shelf registration statement on Form S-3, previously declared
effective by the SEC, on the SEC's website This press release
does not and shall not constitute an offer to sell or the solicitation of an
offer to buy, nor will there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction. Copies of the final prospectus supplement and the
accompanying prospectus may be obtained from J.P. Morgan and Citigroup,
Attention: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)
803-9204; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases.
Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for ground-breaking innovation that improves global health through
safe and effective vaccines.

Forward-Looking Statements

Statements contained in this release using words such as "expects" and
"intends" are forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in the forward-looking statements. These risks and uncertainties include, but
are not limited to: the possible adverse impact on the market price of our
shares of common stock due to the dilutive effect of the securities sold in
the offering; our planned use of the proceeds from this offering; capital
market risks; our ability to raise additional capital when needed; and other
risk factors identified from time to time in the reports we file with
Securities and Exchange Commission (SEC), including our Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which
are available at We caution investors not to place considerable reliance on the
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC for a discussion of these and
other risks and uncertainties. The forward-looking statements in this press
release speak only as of the date of this document, and we undertake no
obligation to update or revise any of the statements. Our business is subject
to substantial risks and uncertainties, including those referenced above.
Investors, potential investors, and others should give careful consideration
to these risks and uncertainties.

CONTACT: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn
Senior Manager, Investor Relations


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.